These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34106028)

  • 1. Mortality Rates After Paclitaxel-Coated Device Use in Patients With Occlusive Femoropopliteal Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Dinh K; Limmer AM; Chen AZL; Thomas SD; Holden A; Schneider PA; Varcoe RL
    J Endovasc Ther; 2021 Oct; 28(5):755-777. PubMed ID: 34106028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality After Paclitaxel-Coated Device Use in Patients With Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Dinh K; Gomes ML; Thomas SD; Paravastu SCV; Holden A; Schneider PA; Varcoe RL
    J Endovasc Ther; 2020 Apr; 27(2):175-185. PubMed ID: 32066315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety of Paclitaxel-Coated Devices for Patients with Peripheral Artery Disease.
    Krawisz AK; Secemsky EA
    Curr Cardiol Rep; 2021 Mar; 23(5):48. PubMed ID: 33738616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality After Paclitaxel-Coated Device Use in Dialysis Access: A Systematic Review and Meta-Analysis.
    Dinh K; Limmer AM; Paravastu SCV; Thomas SD; Bennett MH; Holden A; Varcoe RL
    J Endovasc Ther; 2019 Oct; 26(5):600-612. PubMed ID: 31455140
    [No Abstract]   [Full Text] [Related]  

  • 6. Mortality in patients undergoing revascularization with paclitaxel eluting devices for infrainguinal peripheral artery disease: Insights from a network meta-analysis of randomized trials.
    Kuno T; Ueyama H; Mikami T; Takagi H; Numasawa Y; Anzai H; Bangalore S
    Catheter Cardiovasc Interv; 2020 Oct; 96(4):E467-E478. PubMed ID: 32691953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
    Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
    J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femoropopliteal lesions in patients with ulcerations and gangrene - a single center experience.
    Böhme T; Noory E; Beschorner U; Jacques B; Bürgelin K; Macharzina R; Kuhn LM; Nührenberg T; Neumann FJ; Zeller T
    Vasa; 2021 Feb; 50(2):132-138. PubMed ID: 33118425
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety of paclitaxel-coated devices in the femoropopliteal arteries: A systematic review and meta-analysis.
    Zhang C; Yin G
    PLoS One; 2022; 17(10):e0275888. PubMed ID: 36227807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality Not Correlated With Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon.
    Schneider PA; Laird JR; Doros G; Gao Q; Ansel G; Brodmann M; Micari A; Shishehbor MH; Tepe G; Zeller T
    J Am Coll Cardiol; 2019 May; 73(20):2550-2563. PubMed ID: 30690141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
    Mehrotra S; Paramasivam G; Mishra S
    Curr Cardiol Rep; 2017 Feb; 19(2):10. PubMed ID: 28185166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
    Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
    Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices.
    Secemsky EA; Kundi H; Weinberg I; Jaff MR; Krawisz A; Parikh SA; Beckman JA; Mustapha J; Rosenfield K; Yeh RW
    JAMA Cardiol; 2019 Apr; 4(4):332-340. PubMed ID: 30747949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years.
    Gray WA; Jaff MR; Parikh SA; Ansel GM; Brodmann M; Krishnan P; Razavi MK; Vermassen F; Zeller T; White R; Ouriel K; Adelman MA; Lyden SP
    Circulation; 2019 Oct; 140(14):1145-1155. PubMed ID: 31567024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Mortality Following Paclitaxel Drug-Coated Balloon Angioplasty of Femoropopliteal Lesions in the Real World.
    Böhme T; Noory E; Beschorner U; Jacques B; Bürgelin K; Macharzina R; Gebauer E; Cheung F; Lechner P; Nührenberg T; Zeller T
    JACC Cardiovasc Interv; 2020 Sep; 13(17):2052-2061. PubMed ID: 32593696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of mortality following paclitaxel drug-coated stent angioplasty of femoropopliteal lesions in real world.
    Böhme T; Noory E; Beschorner U; Jacques B; Bürgelin K; Macharzina R; Nührenberg T; Cheung F; Neumann FJ; Zeller T
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1306-1314. PubMed ID: 32930497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
    Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials.
    Cassese S; Byrne RA; Ott I; Ndrepepa G; Nerad M; Kastrati A; Fusaro M
    Circ Cardiovasc Interv; 2012 Aug; 5(4):582-9. PubMed ID: 22851526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-coated peripheral artery devices are not associated with increased mortality.
    Kumins NH; King AH; Ambani RN; Thomas JP; Bose S; Shishehbor MH; Li J; Wong VL; Harth KC; Cho JS; Kashyap VS
    J Vasc Surg; 2020 Sep; 72(3):968-976. PubMed ID: 31917036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.